Antonicelli L, Micucci C, Voltolini S, Senna G E, Di Blasi P, Visonà G, De Marco R, Bonifazi F
Allergy Unit, Department of Internal Medicine, Immuno-Allergic and Respiratory Diseases, Ospedali Riuniti di Ancona, Ancona, Italy.
Allergy. 2007 Sep;62(9):1064-70. doi: 10.1111/j.1398-9995.2007.01470.x.
The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines provide a stepwise treatment to rhinitis, which classifies the disease according to its duration and severity.
The aim of the study was to verify whether these variables influence drug prescriptions for rhinitis and asthma.
A multi-centre cross-sectional pharmaco-epidemiological survey was carried out on 1,610 allergic rhinitis patients and the relationship between the clinical features of rhinitis and drug therapy for rhinitis and asthma was evaluated.
A total of 1,321 adult patients were enrolled. Mild intermittent rhinitis was diagnosed in 7.7%of the patients, moderate/severe intermittent in 17.1%, mild persistent in 11.6%, and moderate/severe persistent in 63.6%. A high level of rhinitis-asthma comorbidity (616/1,321 = 46.6%) was found. The majority of patients [1,060 (80.24%)] were treated. Significant associations between the severity of rhinitis and the presence of therapy (P = 0.008), the use of oral antihistamines (P < 0.001), topical nasal steroids (P = 0.020) and systemic steroids (P = 0.005) were found. A weak association was found between the features of rhinitis and the therapy for asthma, and vice versa the comorbidity with asthma increases the prescription of inhalant (P < 0.001) and oral steroids (P = 0.015) to treat rhinitis.
The severity of rhinitis influences patient request for rhinitis therapy and the type of medication more than the duration. These features of rhinitis seem to poorly influence asthma therapy. As the ARIA classification is able to reveal a relevant impairment notwithstanding therapy, its role in treated patients merits further study.
变应性鼻炎及其对哮喘的影响（ARIA）指南提供了鼻炎的逐步治疗方法，该方法根据疾病的持续时间和严重程度对其进行分类。
本研究的目的是验证这些变量是否会影响鼻炎和哮喘的药物处方。
对1610例变应性鼻炎患者进行了多中心横断面药物流行病学调查，并评估了鼻炎的临床特征与鼻炎和哮喘药物治疗之间的关系。
共纳入1321例成年患者。7.7%的患者被诊断为轻度间歇性鼻炎，17.1%为中度/重度间歇性鼻炎，11.6%为轻度持续性鼻炎，63.6%为中度/重度持续性鼻炎。发现鼻炎-哮喘共病率较高（616/1321 = 46.6%）。大多数患者[1060例（80.24%）]接受了治疗。发现鼻炎严重程度与治疗的存在（P = 0.008）、口服抗组胺药的使用（P < 0.001）、局部鼻用类固醇（P = 0.020）和全身用类固醇（P = 0.005）之间存在显著关联。发现鼻炎特征与哮喘治疗之间存在弱关联，反之，哮喘共病会增加吸入剂（P < 0.001）和口服类固醇（P = 0.015）治疗鼻炎的处方。
鼻炎的严重程度对患者对鼻炎治疗的需求和药物类型的影响大于病程。鼻炎的这些特征似乎对哮喘治疗影响较小。由于ARIA分类尽管经过治疗仍能揭示相关损害，其在接受治疗患者中的作用值得进一步研究。
